Clinical Trials Directory

Trials / Completed

CompletedNCT00907777

Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™

Vaccination With the Pneumococcal Vaccine GSK 1024850A or Prevenar™ at Approximately 4 Years of Age in Children Primed With 3 Doses of GSK 1024850A Vaccine or Prevenar™ and Boosted With 23-valent Pneumococcal Plain Polysaccharide Vaccine

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
52 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
46 Months – 50 Months
Healthy volunteers
Accepted

Summary

The aim of this study is to assess the immune response, safety and reactogenicity following administration of an additional dose of a pneumococcal conjugate vaccine at approximately 4 years of age in children previously vaccinated with 3 primary doses of GSK 1024850A or Prevenar™ vaccine within the first 6 months of life and a booster dose of plain polysaccharide pneumococcal (Pneumovax 23™) vaccine at 11-14 months of age. Antibody persistence will also be assessed at approximately 4 years of age in children previously vaccinated with 3 doses of either GSK 1024850A or Prevenar™ vaccine followed by a booster dose of Pneumovax 23™. This protocol posting deals with objectives \& outcome measures of the extension phase at year 4. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT 00307541). The objectives \& outcome measures of the booster phase are presented in a separate protocol posting (NCT 00333450).

Conditions

Interventions

TypeNameDescription
BIOLOGICALPneumococcal conjugate vaccine GSK 1024850AOne dose of vaccine will be injected intramuscularly into the deltoid.
BIOLOGICALPneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)One dose of vaccine will be injected intramuscularly into the deltoid.

Timeline

Start date
2009-06-23
Primary completion
2009-10-05
Completion
2009-10-05
First posted
2009-05-25
Last updated
2020-11-23
Results posted
2017-01-06

Locations

17 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT00907777. Inclusion in this directory is not an endorsement.